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Abstract.
Background andObjective: Congenital myasthenic syndromes are rare inherited disorders characterized by fatigable weakness
caused by malfunction of the neuromuscular junction. We performed whole exome sequencing to unravel the genetic aetiology
in an English sib pair with clinical features suggestive of congenital myasthenia.
Methods: We used homozygosity mapping and whole exome sequencing to identify the candidate gene variants. Mutant protein
expression and function were assessed in vitro and a knockdown zebrafish model was generated to assess neuromuscular junction
development.
Results: We identified a novel homozygous missense mutation in the SLC25A1 gene, encoding the mitochondrial citrate carrier.
Mutant SLC25A1 showed abnormal carrier function. SLC25A1 has recently been linked to a severe, often lethal clinical pheno-
type. Our patients had a milder phenotype presenting primarily as a neuromuscular (NMJ) junction defect. Of note, a previously
reported patient with different compound heterozygous missense mutations of SLC25A1 has since been shown to suffer from a
neuromuscular transmission defect. Using knockdown of SLC25A1 expression in zebrafish, we were able to mirror the human
disease in terms of variable brain, eye and cardiac involvement. Importantly, we show clear abnormalities in the neuromuscular
junction, regardless of the severity of the phenotype.
Conclusions: Based on the axonal outgrowth defects seen in SLC25A1 knockdown zebrafish, we hypothesize that the neuro-
muscular junction impairment may be related to pre-synaptic nerve terminal abnormalities. Our findings highlight the complex
machinery required to ensure efficient neuromuscular function, beyond the proteomes exclusive to the neuromuscular synapse.
Keywords: Congenital myasthenic syndrome, neuromuscular junction, mitochondrial citrate carrier, SLC25A1
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INTRODUCTION
Congenital myasthenic syndromes (CMS) are a
group of inherited neuromuscular disorders in which
the integrity of the neuromuscular junction (NMJ)
is compromised [1]. The clinical hallmark of these
syndromes is fatigable weakness, which is often treat-
able. Most of CMS patients present with fluctuating
ocular, bulbar, respiratory and limb weakness [2, 3].
Over the past 25 years, more than 19 genes have been
implicated in congenital myasthenic syndromes [4, 5].
These usually express proteins involved in neuromus-
cular synapse development and function; and most
mutations identified so far have involved post-synaptic
proteins.
However, in spite of recent progress, a proportion
of congenital myasthenic syndrome patients remain
genetically undiagnosed [2]. Thus, one can speculate
that some of these undiagnosed patients may harbour
very rare private mutations in a particular gene. Alter-
natively, these patients may have mutations in genes
encoding ubiquitous proteins that can primarily present
as an NMJ defect but may also have a much broader
spectrum of disease. A good example includes the
recently discovered CMS related to mutations in genes
that were until then implicated in congenital glyco-
sylation disorders [6, 7]. Another example includes
mutations in PLEC1 and LAMB2 genes in which muta-
tions can lead to a CMS phenotype combined with skin
or kidney disease respectively [8, 9].
Whilst mitochondrial gene defects can cause a myr-
iad of neurological disorders including myopathies and
neuropathies, these have not been specifically impli-
cated in defects of the neuromuscular junction [10, 11].
SLC25A1 is a mitochondrial citrate carrier believed
to be a key player in fatty acid and sterol biosynthesis,
gluconeogenesis and glycolysis [12]. More recently,
it has been proposed that it may also play a role in
the maintenance of chromosome integrity and in the
regulation of autophagy [13, 14].
In the mitochondria, SLC25A1 mediates the
exchange of mitochondrial citrate/isocitrate with
cytosolic malate. The exported citrate is cleaved into
acetyl-coenzyme-A and oxaloacetate by ATP-citrate
lyase [12, 15]. Acetyl-coenzyme A is the main sub-
strate of lipid and sterol biosynthesis in the cell while
oxaloacetate is usually reduced to malate and diverted
back into the mitochondria for further exchange with
mitochondrial citrate. Citrate can also inhibit cytosolic
phosphofructokinase 1, thus indirectly influencing the
rate of glycolysis. Both citrate and malate are involved
in regulating NADPH content in the cell [15, 16].
The recent discovery of several patients harbouring
mutations in this mitochondrial carrier has confirmed
that this is a protein of critical biological importance
in humans [17, 18]. Indeed SLC25A1 dysfunction
was shown to interfere with brain, eye and perhaps
neuromuscular development, in addition to causing a
distinctive urinary organic acid profile. Whether this
metabolic disturbance itself is sufficient to explain the
phenotype is unclear at present. However, it is likely
that other factors like oxidative stress, ROS toxicity
and NADPH content are also relevant.
We performed whole exome sequencing in an
affected sib pair from a consanguineous family from
Northern England. The patients had remained geneti-
cally undiagnosed for more than 23 years, having had a
suspected clinical diagnosis of congenital myasthenia
with a reported response to pharmacotherapy.
MATERIALS AND METHODS
Patient data
Patients were selected from the Newcastle MRC
Neuromuscular Centre, Institute of Genetic Medicine,
Newcastle upon Tyne. Our patients were 2 Caucasian
siblings born to two healthy consanguineous parents
(first cousins), from Newcastle in the North of England.
The index case was a male patient who presented with
fatigable weakness since early infancy mainly involv-
ing his limbs. Neurophysiological studies showed no
evidence of neuropathy or myopathy. Although there
was no decrement on repetitive nerve stimulation, there
was marked jitter in several muscles in keeping with
impaired neuromuscular junction transmission. His
sister presented in a similar fashion but exhibited mod-
erate intellectual disability. Given the positive family
history, evidence of fatigable weakness with abnormal
jitter, a diagnosis of CMS was suspected. Appropriate
consent for research was obtained from each patient
and any family member involved in this study.
Genomic DNA was extracted from venous blood
taken from both siblings and unaffected family mem-
bers, by automated DNA extraction on the M48 Bio
Robot using the MagAttract DNA blood Mini M48
kit (Qiagen 951336) as part of the routine service per-
formed by the Northern Genetics Service molecular
laboratory.
Study of the patient neuromuscular junction
Repetitive nerve stimulation and single fibre EMG
(SFEMG) were carried out on the index case at age 20
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and repeated at 21 years. 3 Hz stimulation was used to
search for decrement and we checked for facilitation
after 20 sec of voluntary maximum contraction.
The number of endplate AChR was determined
as previously described [19]. Briefly, muscle bundles
were dissected, labelled with 125I-a-BuTX, prior to
staining for acetylcholinesterase. The number of end-
plates in a given region was determined in combination
with respective level of 125I-a-BuTX binding to gen-
erate the number of receptors per endplate. 35 NMJ
were checked to determine (miniature endplate poten-
tials (MEPPS) and quantal content with between 1 and
62 MEPPS per NMJ.
Homozygosity mapping
In order to identify the chromosomal location of the
disease causing mutation in this family, we carried out
genome wide genotyping of SNPs using Illumina 300K
chip (Illumina, San Diego, Ca). This was performed
to identify regions of homozygosity shared by both
affected siblings, since we presumed the inherited dis-
ease to be recessive caused by a homozygous mutation
segregating on the same ancestral haplotype.
Whole exome sequencing and data analysis
Given that the family history was highly suggestive
of autosomal recessive inheritance (healthy parents,
two affected children and parental consanguinity),
and that most CMS are recessive in inheritance, we
applied the recessive model looking for genes contain-
ing homozygous or at least 2 heterozygous changes
shared between siblings (see supplementary material
for the details of exome filtering pipeline).
CGH array analysis
CGH array was carried out to analyse copy num-
ber variations on the female patient who exhibited
intellectual disability. CytoChip ISCA 180 K V1.0
oligonucleotide array (BlueGnome) was used accord-
ing to the manufacturer´s instructions (BlueGnome).
RsaI and AluI digested DNA products (patient’s
DNA as well as reference DNA) from periph-
eral blood were labelled by random priming using
either Cy3-dUTP or Cy5-dUTP) and hybridized at
65◦C for 24 h. Scanning and image acquisition was
done on an Agilent microarray scanner. Data anal-
ysis was performed using BlueFuse Multi software
(BlueGnome).
Construction of the expression plasmids and
bacterial expression
The coding sequence of the yeast orthologue citrate
carrier CIC (CTP1, NM 001178639.1) was ampli-
fied from S. cerevisiae genomic DNA via PCR and
the mutations were introduced by site-directed muta-
genesis as described in QuikChange® Site-Directed
Mutagenesis Kit from Stratagene. Ctp1p and its
mutated form (p.R241Q, p.R276H and p.G117D) were
overexpressed as inclusion bodies in the cytosol of E.
coli strain BL21 (DE3). Inclusion bodies were puri-
fied on a sucrose density gradient and washed at 4◦C,
first with Tris-EDTA buffer (10 mM Tris–HCl, 1 mM
EDTA, pH 7.0), then twice with a buffer containing
Triton X-114 (3%, w/v), 1 mM EDTA, 20 mM Na2SO4
and 10 mM PIPES pH 7.0, and finally with the Tris-
EDTA buffer pH 7.0. The proteins were solubilized
in 1.7% sarkosyl (w/v). Eventual small residues were
removed by centrifugation (20800 × g for 10 min at
4◦C).
Reconstitution of the recombinant proteins into
liposomes and transport assays
The recombinant proteins solubilized in sarkosyl
were reconstituted by cyclic removal of detergent as
described [20] with some modification. The reconstitu-
tion mixture consisted of phospholipids in the form of
sonicated liposomes (10 mg), protein solution (25l,
about 9g), 10% Triton X-114 (70l), 10 mM citrate
(35l), cardiolipin (0.7 mg), 10 mM PIPES/NaOH pH
7.0 and water (final volume 700l). The mixture was
recycled 13-fold through an Amberlite column pre-
equilibrated with 10 mM PIPES-NaOH (pH 7.0) and
50 mM NaCl. All operations were performed at 4◦C
except the passages through Amberlite, which were
carried out at room temperature. Approximately 20%
of WT or mutated CIC proteins were reconstituted.
External citrate was removed from proteoliposomes on
Sephadex G-75 columns pre-equilibrated with 50 mM
NaCl and 10 mM PIPES at pH 7.0 (buffer A). Trans-
port at 25◦C was started by adding 0.1 mM [14C]
Citrate (from PerkinElmer, Inc) to proteoliposomes
and terminated by addition of 20 mM pyridoxal 5′
phosphate and 20 mM of bathophenanthroline. In con-
trols, inhibitors were added with the labelled substrate.
The external substrate was removed by Sephadex G-
75 columns pre-equilibrated with buffer A, and the
entrapped radioactivity was counted. The experimental
values were corrected by substracting control values
and the initial transport rate was calculated from the
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time-course of substrate uptake by proteoliposomes
[21].
Mitochondrial membrane potential assessment in
fibroblasts
Fibroblasts from the affected sibling harbouring
the SLC25A1 variant c.740G > A; p.R247Q and con-
trol fibroblasts were grown in DMEM (high glucose).
Membrane potential was measured by fluorescence
microscopy using the tetramethylrhodamine methyl
ester (TMRM) probe [22], while mitochondrial mor-
phology was investigated using MitoTracker® Red
CMXRos. MitoTracker® Red CMXRos and tetram-
ethylrhodamine methyl ester (TMRM) were purchased
from Life Technologies.
Fluorescent images of treated cells were acquired
and fluorescence intensities were analyzed, as pre-
viously described [23], using a Zeiss Axiovert
200 microscope equipped with a Photometrics Cas-
cade 512B CCD camera (Roper Scientific) and the
MetaFluor software (Universal Imaging).
Western blotting
Immunoblot analysis was performed using
100 × 103 cells (patient and control fibroblast). The
cells were rinsed with ice-cold PBS and lysed using
RIPA buffer. Total proteins were heated at 100◦C for
5 min, separated by SDS-PAGE and transferred to
nitrocellulose membranes. The membrane was then
incubated at room temperature with anti-SLC25A1
polyclonal antibodies raised in rabbit against recom-
binant rat SLC25A1 carrier or mouse monoclonal
antibodies against the  subunit of human F1-ATPase
(BD Biosciences). Antigen–antibody complexes were
detected using anti-rabbit or mouse IgG-coupled
horseradish peroxidase (Pierce, Thermo Scientific), in
combination with the ECL system (Merk Millipore).
Multiple sequence alignment and evolutionary
pressure analysis
A multiple sequence alignment of citrate carrier
(CIC) orthologs from various species and other mito-
chondrial carriers was obtained using ClustalW [24].
The functional or structural relevance of the mutated
residues of the mitochondrial citrate carrier protein was
estimated according to a scoring system based on the
evolutionary pressure acting on each amino acid as
described previously [25].
SLC25A1 knockdown in zebrafish embryos
A BLAST search of zebrafish transcripts with
the human SLC25A1 protein sequence as input
revealed the presence of three homologues in the
zebrafish genome: two on chromosome 10: SLC25A1a
(NM 200607), SLC25A1b (XM 003199276.2) and
one on chromosome 8 (SLC25A1c). Only SLC25A1a
and SLC25A1b from chromosome 10 are expressed in
zebrafish (Supplementary Figure 1).
Zebrafish husbandry and observation
The Golden strain (slc24a5b1/+) of zebrafish
was used in this study (Zebrafish International
Resource Centre (ZIRC), Oregon). Zebrafish embryos
were raised at 28.5◦C and staged in hours or days
post-fertilization (hpf or dpf) according to standard
procedures. Video recordings of embryos and larvae
were taken with a Leica dissection stereomicroscope
equipped with a Chameleon digital camera (model
CMLN-13S2M, Chameleon). Touch-evoked swim-
ming response of embryos was elicited by touching
the head or the tail of the embryos with a fine pipette
tip. Light microscope images of injected and non-
injected embryos were taken with a digital camera
(model LEICA DFC 420C) mounted on a Leica
dissection stereomicroscope. Procedures involving
experimentation on animal subjects were done in
accordance with the local institutional guide.
Antisense morpholino oligonucleotide knockdown
Antisense morpholino oligonucleotides (MOs)
were purchased from Gene Tools LLC (Pilomath,
OR). The MOs were designed with the mRNA
sequence of the zebrafish SLC251A orthologues and
genomic sequences available from public databases
(SLC25A1A GeneID: 393579, accession number:
NM 200607.1) and (SLC25A1B GeneID: 795332,
accession number: XM 003199276.2) and the corre-
sponding genomic DNA sequence obtained from the
zebrafish chromosome 10 assembly.
We established two MOs, one per gene orthologue.
Both MOs are splice-blocking and directed against
the splice donor site of exon 3. The following
two morpholinos were used: (MO1: zSLC25A1a 5′-
AGATGAATCTTTCTTACCGTACTGC-3′ and MO2:
zSLC25A1b 5′-GCGGGTTAGGAAACACTCACCTC
AC-3′). Both MOs are expected to interfere with
the splicing process and lead to a disruption of
the protein open reading frame and premature
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translation termination after 25 missense amino
acids. The Gene Tools standard control MO (5′-
CCTCTTACCTCAGTTACAATTTATA-3′) targeting
a human beta-haemoglobin gene was used as a
negative control for the effects of MO injection.
We also used the Gene Tools anti-p53 MO (5′-
GCGCCATTGCTTTGCAAGAATTG-3′) to suppress
any non-specific apoptotic effects that can be induced
by some MOs.
MOs were suspended in 1x Danieau solution
(58 mM NaCl, 0.7 mM KCl, 0.4 mM MgSO4, 0.6 mM
Ca(NO3)2, 5 mM HEPES; pH 7.6) with phenol red as
an injection indicator.
Embryos were injected with both morpholinos sep-
arately to determine the optimal concentration to
produce the best range of phenotypes and then with
both MOs simultaneously. 5 ng SLC25A1a MO and
2.5 ng SLC25A1b produced the best range of phe-
notypes. Four independent MO injection experiments
were performed for each MO and at least 500 injected
embryos were evaluated in total for each MO.
RNA isolation and RT-PCR
RNA from approximately 30 zebrafish embryos was
isolated with Trizol reagent (Invitrogen, Life Tech-
nologies) following the manufacturer’s instructions.
Reversetranscriptionwasperformedwith1or2gtotal
RNA as template with the Superscript III First-Strand
Synthesis System (Invitrogen, Life Technologies) and
MolTaq DNA polymerase (Molzym). Regions of inter-
est were amplified with compatible primers.
Immunofluorescence staining
Whole-mount immunofluorescence staining and
imaging of zebrafish embryos was conducted as pre-
viously described. In brief, NMJ were visualized
with Alexa Fluor® 594 conjugated alpha-bungarotoxin
(Invitrogen, Life Technologies, 1 mg/ml) and a mouse
monoclonal anti-SV2 (synaptic vesicle protein 2) anti-
body (Developmental Studies Hybridoma Bank, Iowa
City, IA; dilution 1:200). Alexa Fluor 594 conjugated
phalloidin (Sigma-Aldrich) was used at a concentra-
tion of 5g/ml to label actin.
RESULTS
Clinical phenotype
This was a consanguineous family of Caucasian ori-
gin from the north of England with 2 affected siblings
and one healthy offspring. Both parents were report-
edly healthy. The index case is a 33-year-old man
who was the product of normal pregnancy and birth
but displayed some speech and motor developmental
delay. In early childhood, he developed intermittent leg
weakness, which was exercise induced and improved
with rest. He had no ocular, bulbar or respiratory dif-
ficulties. He had mild learning difficulties but was
able to attend mainstream schooling and settle in full
time employment. His neuromuscular symptoms have
been stable over the years. Of note, he recently devel-
oped obsessive-compulsive tendencies. Examination
showed mild bilateral ptosis but no ophthalmoplegia.
He has dysarthria with fatigable speech. Muscle tone
and power were normal at rest. However, there was
fatigability with exercise. He had bilateral pes cavus
as well as calf hypertrophy bilaterally. Reflexes were
reduced at rest with clear potentiation with exercise
(Table 1).
The sister, who is now 19 years, is the product of nor-
mal pregnancy and birth. She had delayed psychomotor
milestones, more marked than her brother. She devel-
oped recurrent falls in early infancy with clear fatigable
weakness in all her limbs. She complained of intermit-
tent double vision but she had no bulbar or respiratory
difficulties. The course of her illness was static.
Examination showed some facial weakness with no
ophthalmoplegia or ptosis. She had mild neck flexion
weakness with fatigable arm and leg weakness. She is
ambulant. Reflexes were normal. This patient currently
attends a special need college (Table 1).
Neurophysiology was performed in consecutive
years when the index patient was aged 20 and 21 years
with similar outcome. At both examinations, repetitive
nerve stimulation of ADM (abductor digiti minimi)
and anconeus at 3 Hz stimulation showed no decre-
ment of CMAP (compound muscle action potential)
and no facilitation of CMAP after maximum voluntary
contraction for 20 sec. SFEMG (single fibre EMG) on
EDC (extensor digitorum communis) showed 72% of
potential pairs have increased jitter or jitter with block-
ing: −25% were normal, 52% showed increased jitter,
20% showed block, from 25 pairs sampled. Analysis of
jitter showed a MCD (mean consecutive difference) of
78.5 ± 44.4 micros from non-blocking pairs. At age 21,
SFEMG on EDC showed 81% of potential pairs have
increased jitter or jitter with blocking: 19% were nor-
mal, 62% showed increased jitter, 19% were blocking,
from 16 pairs. MCD was 71.6 micros.
Muscle biopsy was normal although electron
microscopy of an earlier muscle biopsy suggested
enlarged mitochondria and an increase in their number.
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Table 1
Clinical features of the 3 patients with mutations in the SLC25A1 gene presenting with a phenotype suggestive of congenital myasthenia
Case 1 Case 2 Case 3
Gender/age/ethnicity Male/33y/English Female/19y/English Female/18 m/Israeli
Mutation p.R247Q p.R247Q p.G130D; p.R282H
Progression Stable with some long term fluctuations Stable progressive
Age at onset Less than 2 years Less than 2 years 10 days
Symptoms at onset Fluctuating leg weakness Fluctuating arm and leg
weakness
Poor suck, hypotonia, apneas
Psychomotor delay/intellectual
disability
No but developed obsessive compulsive
disorder in adulthood
Yes Yes
Ocular involvement Ptosis Ptosis Optic nerve hypoplasia
Bulbar weakness No No Yes
Apneic crises No No Yes
Epilepsy No No Yes
Agenesis of the corpus callosum No No Yes
Hearing loss No No Yes
Elevated urinary organic acids No No Yes
Abnormal jitter with block Yes Not done Yes
Positive response to treatment Yes Equivocal No
We were unable to access the biopsy to obtain further
details. Only a crude determination of endplate mor-
phology was obtained at the time. In some cases the
endplates appeared enlarged, but there are not detailed
studies of this. Analysis of an anconeus muscle biopsy
showed normal endplate AChR number. Consistently
MEPP amplitude and quantal content in in vitro elec-
trophysiology was within the normal range.
Muscle histology was normal with normal res-
piratory chain enzyme activity and no evidence of
mitochondrial DNA deletions on muscle analysis.
Blood and CSF lactate levels were normal. Genetic
testing for MELAS, MERRF, LHON, NARP was neg-
ative. Free and total carnitine levels were normal.
Acetylcholine receptor antibodies were negative. CT
and more recently MRI of the brain with spectroscopy
were normal.
The index case was initially treated with pyridostig-
mine with no clear benefit after which he was instigated
on 3,4-DAP with a favourable response. His sister
received pyridostigmine since early childhood, which
she continues to this date. It is unclear whether she has
any benefit from this treatment.
While the index case had normal karyotype, we
identified a 30.4 Mb deletion Xq25 to Xq28, Posi-
tion 122,440,897-154,886,079 using CGH array in the
affected sister. The parents have not yet been tested for
this deletion.
The third patient was described earlier and is now
aged 3 years [17]. She presented soon after birth
with poor sucking, recurrent apnoea, apathy and hypo-
tonia. Corpus callosum agenesis and optic atrophy
were found. Subsequently, psychomotor developmen-
tal delay, reduced spontaneous movement as well as
seizures were documented. Recurrent apnoea and poor
respiratory effort necessitated tracheostomy. She is
now ventilator-dependent. Urinary organic acid analy-
sis revealed a large peak of 2-hydroxyglutaric acid and
Krebs cycle intermediates. Mitochondrial functions in
cultured skin fibroblasts disclosed decreased growth in
glucose free medium, increased ROS production and
decreased mitochondrial membrane potential but nor-
mal ATP content. Exome sequencing led to the iden-
tification of two SLC25A1 variants, chr.22:19163734
C->T resulting in (p.R282H) and chr.22:19165292
C->T resulting in (p.G130D). Kinetic studies using
mutant recombinant protein into liposomes showed
complete loss of transport function for the former
variant and only a small residual activity for the lat-
ter. Single-fibre EMG at the age of 2 years revealed
markedly increased jitter and blocking. The myas-
thenic symptoms did not fluctuate and did not improve
with 3,4-DAP, pyridostigmine and ephedrine (Table 1).
Our two affected siblings were born to healthy
consanguineous parents indicating a recessive pat-
tern of inheritance. The following CMS genes
were excluded by targeted linkage analysis: COLQ,
CHRNA1, CHRNB1, CHRNE, CHAT, RAPSN, MUSK,
SCN4A, DOK7 and GFPT1. Sanger sequencing was
carried out to further exclude CHRNA1, CHRNB1,
CHRND, CHRNE, RAPSN, CHAT, DOK7 and COLQ.
Identification of mutations in SLC25A1 gene
Homozygosity mapping by genome wide SNP geno-
typing revealed 4 large homozygous blocks on chro-
mosome 5 (7.97 Mb); chromosome 13 (19.43 Mb);
chromosome 16 (17.02 Mb) and chromosome 22
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(10.62 Mb) shared by both siblings. Because these
homozygous blocks were very large and contained
many genes, we decided to proceed with whole exome
sequencing in both siblings.
Whole exome sequencing generated an average of
8.73 gigabases (Gb) of mappable sequences per patient
and 53.92% of reads mapped to targets. 87% of tar-
geted variants had a 10 fold coverage, which was used
for variant calling in our filtering pipeline. Filtering
of variants shared by both siblings by restricting our
search to coding, rare (frequency <1%), predicted to
be deleterious changes, allowed us to shortlist one
homozygous variant in the SLC25A1 gene (exon7:
c.740G > A; p.R247Q, GenBank: NM 005984). This
variant was located in the large homozygous block
on chromosome 22 and led to the substitution of a
highly conserved positively charged arginine residue
to a neutral glutamine residue. It is worth noting that
the same mutation was identified using whole genome
sequencing of the older sibling. A second rare vari-
ant was identified in CLTL1, c.719A > G; p.N240S
(rs147685377). However, this variant was identified
C
Fig. 1. Sequence alignment of mitochondrial citrate carrier (SLC25A1) from different organisms (panel A) and other members of mitochondrial
carrier family (panel B). Accession numbers for each species/carrier is given. Panel C shows structural comparative model of human CIC and
docking of citrate. The 3D comparative model of human CIC is reported in white cartoon representation. The six transmembrane helices are
indicated by black labels (H1-H6). Two of the three helices parallel to the membrane planes are also labelled (h12 and h56). The citrate ligand
is shown in cyan licorice. The pathogenic mutations p.R247Q (this work), p.G130D, p.R282H [17] are displayed in red surf representation.
82 A. Chaouch et al. / Mutations in the Mitochondrial Citrate Carrier SLC25A1
at frequencies between 0.1% and 0.7% in public and
“in house” databases suggesting that this is likely to be
a benign variant.
The SLC25A1 variant (c.740G > A; p.R247Q) segre-
gated in the family according to an autosomal recessive
transmission pattern. Both parents were heterozygous
for the mutant allele whilst the unaffected brother was
homozygous for the wild type allele.
We further screened a total of 58 patients from our
CMS cohorts (Munich, Newcastle, Oxford), but did not
identify additional pathogenic variants in SLC25A1.
Exome sequencing of 100 undefined neuromuscular
cases including CMS cases did not identify any other
SCL25A1 variants.
After obtaining the above described results, we
proceeded to investigate a neuromuscular transmis-
sion defect in a Jewish Ashkenazi patient (patient
3 described above), previously described by us with
compound heterozygous disease-causing mutations of
SLC25A1 gene [17].
Biochemical characterization of the SLC25A1
variants
SLC25A1 consists of eight exons which encode the
mitochondrial citrate carrier, a 311 amino acid pro-
tein. The percentage of identical amino acids between
the yeast and the mammalian orthologous mitochon-
drial carriers is generally not much higher than that
observed between the different members of the mito-
chondrial carrier family (25–30% of identical amino
acids; [26]). Notably the yeast Ctp1p shares 37% of
sequence identity (52% of sequence similarity) with
the human citrate transporter coded by SLC25A1.
Nonetheless, S. cerevisae has been shown to be useful
for studying the functional effect of pathogenic muta-
tions in human mitochondrial transporters that proved
difficult to be over-expressed in bacteria [17, 27]. As
shown in Fig. 1A, arginine 247 is highly conserved
in SLC25A1 of fungi and metazoan and also con-
served in several other mitochondrial carriers (Fig. 1B).
This residue belongs to the transmembrane helix 5
and corresponds to the second basic amino acid of
the sequence motif PX[D/E]XX[K/R]X[K/R], which
is characteristic of members of the mitochondrial car-
rier family [28]. By comparison with the crystallized
structure of the ADP/ATP carrier [29] it is observed
that R247, together with the two residues of the citrate
carrier located at the same height on transmembrane
helix 1 (Q52) and 3 (K149), is involved in ionic inter-
actions with the acidic residues of the second part of
the MCF sequence motif [D/E]Gx5Ar[K/R]G at the
Fig. 2. Functional characterization of the wild-type (WT) and the
p.R241Q Ctp1. The uptake rate of (14C) citrate was measured by
adding 0.1 mM of (14C) citrate to proteoliposomes reconstituted with
purified WT or with the mutated Ctp1 protein. The proteoliposomes
were preloaded internally with 10 mM of citrate. The means and SDs
from five independent experiments are shown (*p < 0.01, two-tailed
unpaired Student’s t-test).
beginning of even transmembrane helices (Fig. 1c,
Supplementary Figures 2, 3). These intra-repeat inter-
actions participate in alternate closing and opening
of the carrier on the matrix side during the substrate
transport cycle [30].
Kinetic analysis of the R241Q Ctp1p mutant was
performed upon reconstitution of purified recombinant
protein into liposomes. As shown in Fig. 2, the sub-
stitution of R241, corresponding to R247 in human
SLC25A1, with glutamine causes a strong impair-
ment of transport activity compared to WT Ctp1p even
though a significant residual activity was conserved.
This decrease could only in part be compensated by
an increase (approximately 30%) of SLC25A1 protein
abundance as indicated by Western Blotting analysis
carried out on cultured skin fibroblasts of the affected
brother and control cells (Fig. 3). No evidence of
altered mitochondrial content or network morphol-
ogy was observed (Supplementary Figure 4A) and
a small (not significant p > 0.05) decrease of mito-
chondrial membrane potential was measured in patient
fibroblasts compared to control cells (Supplementary
Figure 4B).
We have recently developed an in silico approach
to measure the evolutionary constraint acting on each
amino acid residue of the human mitochondrial car-
riers and, consequently, to predict its importance in
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Fig. 3. Total lysates of fibroblast cells (patient and control) were
subjected to Western blot analysis upon separation by SDS-PAGE
and SLC25A1 (∼31-kDa) and -ATPase (∼55-kDa) levels were
determined by densitometric analysis. The relative ratio was calcu-
lated and the means and SDs from three independent experiments
are shown (*p < 0.01, two-tailed unpaired Student’s t-test).
Fig. 4. Transport assay of reconstituted CTP1p wild type (WT) and
mutated Ctp1p forms into liposomes. At time zero 0.1 mM (14C)
citrate was added to liposomes reconstituted with the recombinant
wild-type or mutants and containing 10 mM citrate. At the indi-
cated times, the uptake of the labeled substrate was terminated by
adding 20 mM pyridoxal 5′-phosphate and 20 mM bathophenanthro-
line. Similar results were obtained in four independent experiments.
preserving the carrier function [25]. Considering all
the 216 residues previously scored for SLC25A1 [25],
R247 is in the bottom 50% of scores, i.e. below a
median threshold of 4.68. It is worth noting that all
other known mutated residues in SLC25A1-associated
pathology have higher scores, including the previously
biochemically characterized p.G130D and p.R282H
(Table 2, Fig. 4). According to this scoring method,
the R247 residue of SLC25A1 is predicted to be less
functionally relevant than other mutated SLC25A1
residues, consistent with a milder clinical phenotype,
normal levels of urinary 2-hydroxyglutarate and higher
protein activity (Table 2).
Zebrafish SLC25A1 knockdown
To explore the effect of reduced expression of
SLC25A1 on the neuromuscular junction, we knocked
down the 2 SLC25A1 orthologues (SLC25A1a and
SLC25A1b) that are expressed in zebrafish embryos,
by injection of antisense MOs. Mis-spliced transcripts
were detected alongside the wild-type transcript at
48hpf following injection of both SLC25A1a and
SLC25A1b MOs (Supplementary Figure 5).
Knockdown of neuromuscular junction proteins
usually affects motility and swimming behaviour of
injected embryos. Indeed, MO-injected embryos dis-
played altered tail morphology (Fig. 5), and swimming
and touch-evoked escape responses at 48 hpf were
impaired. Histologically, we observed normal muscle
morphology while NMJ development was abnormal
(Figs. 6, 7). Motor axon terminal showed short and
erratic outgrowth toward the muscle fibre with no
evidence of complete synapse formation, pointing
towards an underlying presynaptic defect (Fig. 6). NMJ
morphology and function were normal in embryos
injected with a standard control MO and in non-
injected wild type embryos (data not shown). In
addition, knockdown embryos often showed oedema
of the hindbrain, heart, yolk sac and tail (Fig. 5, Supple-
mentary Figure 6). Abnormal heart development was
observed with increased severity of phenotype with
reduced blood flow to the tail (Supplementary video).
Knockdown embryos displayed these characteristics
in both the presence and absence of the apoptotic sup-
pressing anti-p53 MO (Supplementary Figures 7, 8).
DISCUSSION
The diagnosis of congenital myasthenia is based
on the presence of early onset fatigable weakness,
impaired NMJ transmission, absence of auto antibod-
ies and response to treatment [5, 31]. The two affected
siblings in our study had clinical features consistent
with CMS in addition to variable intellectual disability,
which is uncommon in CMS. The presence of the high
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Table 2
Phenotype and mutations of patients affected by SLC25A1-associated pathologies [17, 18]. A prediction of the functional relevance of each
residue is also reported (residue-specific score), as calculated in [25]. (a) agenesis of the corpus callosum and optic nerve hypoplasia with marked
jitter on SFEMG(b) neonatal epileptic encephalopathy and absence of developmental progress. (c) Percentage of activity of the mutated yeast
orthologous protein compared to the yeast wild-type protein [[17] and this study]. (d) Percentage of citrate uptake in human mutated fibroblasts
compared to human control fibroblasts [18]. 2-HG: urinary 2- hydroxyglutarate
Patients Clinical phenotype 2-HG levels Human mutation SLC25A1 Activity (%) Residue-specific score
Present study mild Normal p.R247Q 40 (c) 3.38
[17] severe (a) High p.G130D 25 (c) 5.50
p.R282H 0 (c) 5.61
[18] patient 1 severe (b) High p.S193W 12.9 (d) 5.51
[18] patient 2 – High p.R282G 12.3 (d) 5.61
[18] patient 3 severe (b) High p.R282C 6.1 (d) 5.61
[18] patient 5 severe (b) High p.G167R 19.8 (d) 5.10
[18] patient 6 severe (b) High p.P45L – 5.00
[18] patient 8 severe (b) High p.E144Q – 5.04
[18] patient 10 severe (b) High p.M202T – 5.33
p.Y297C – 4.89
Fig. 5. Live embryos imaged at 48hpf following co-injection of SLC25A1a (5 ng) and SLC25A1b (2.5 ng). Injected embryos demonstrate a
range of phenotypes with mild to severe morphological abnormalities. Embryos exhibit a developmental delay with curvature and shortening
of the tail and also oedema of the hindbrain, heart, yolk sac and tail. Scale bars: 500m.
proportion of pairs showing jitter and the significant
blocking on SFEMG, indicated a problem with neu-
romuscular transmission and thus a contributing NMJ
disorder.
It is worth noting that the disease course in these two
patients was relatively mild compared to other CMS
patients [2], with little evidence of progression.
The X chromosomal deletion identified in the
female, but not the male patient could have con-
tributed to her intellectual disability. This is a large
heterozygous deletion (30 Mb), which contains 273
genes (full gene list available on request), including
FMR1, which is responsible for fragile-X-syndrome.
In a male individual, a contiguous gene syndrome
with a much more severe or probably lethal phenotype
would be expected.
We performed homozygosity mapping and whole
exome sequencing to determine the underlying genetic
cause in our family and successfully identified a novel
homozygous mutation in the SLC25A1 gene. This was
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Fig. 6. Neuromuscular junctions following injection with SLC25A1 MOs. Non-injected control Wild Type Golden embryos (left) and SLC25A1
MO injected embryos were stained for postsynaptic AChR (-bungarotoxin, red staining) and presynaptic nerve endings (SV2 antibody, green
staining). Combined SLC25A1 MO (a 5 ng & b 2.5 ng) injected 48hpf embryos demonstrate short motor axons and erratic outgrowth toward
the muscle fibre. Scale bar: 50m.
the only, novel variant affecting a highly conserved
residue, that was expressed in muscle and nerve and
predicted to be disease causing. Further corroborat-
ing evidence arose from demonstration of a NMJ
defect in a previously described patient with a dif-
ferent compound heterozygous mutation of SLC25A1
gene [17]. The phenotype of the latter was associated
with a neurodevelopmental disorder manifesting as
profound psychomotor retardation, hypotonia, apnoeic
crises, poor feeding, epilepsy, postnatal microcephaly,
sensori-neural deafness, agenesis of the corpus cal-
losum (ACC) and hypoplastic optic nerves. She had
raised urinary hydroxyglutaric acid levels and Krebs
metabolites [17].
In addition, a subsequent report described a series of
13 patients, from 12 unrelated families, with a severe
clinical phenotype and recessive SLC25A1 mutations
[18]. 8 of these patients were deceased a few months
after birth (range 1 month - 5 years 1 month). All exhib-
ited developmental delay, hypotonia and seizures [18].
A large peak of 2 hydroxyglutaric acid was identified
in all patients previously reported with SLC25A1muta-
tions, but no variants were identified in corresponding
genes causing L2 or D2 hydroxyglutaric aciduria, sug-
gesting that this metabolic disturbance is secondary
to defects in SLC25A1. We have tested our 2 patients
and found normal urinary organic acid analysis in
keeping with a milder phenotype. SLC25A1 is well
conserved across species and was shown to be critical
in intermediary metabolism, glucose induced insulin
secretion and chromatin integrity [13, 14, 28, 32].
The chromosomal location of this gene (22q11.2) also
attracted some attention as this is either translocated
or amplified in some tumours and deleted in DiGeorge
syndrome and possibly schizophrenia [33, 34]. How-
ever, until recently, SLC25A1 was not directly linked
to any human disease [17, 18].
Knockdown of several CMS genes in zebrafish
embryos has been recently used to demonstrate direct
or indirect effects on the neuromuscular junction [35,
36]. Interestingly, SLC25A1 knockdown showed vari-
able phenotype ranging from mild, moderate to severe;
with confirmed aberrant NMJ development and func-
tion similar to what was seen in the 2 affected siblings.
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Fig. 7. Muscle morphology following injection with SLC25A1 MOs. WT and control MO injected embryos (left) and SLC25A1 MO injected
embryos (centre and right) were stained for F-actin with Alexa Fluor® 594 conjugated phalloidin (5g/ml). WT embryos and those injected
with a standard control MO showed normal muscle morphology. Combined SLC25A1 MO with and without the addition of anti-p53 MO also
demonstrate normal muscle morphology. Scale bar: 50m.
At the level of the neuromuscular junction, we were
able to show intact muscle fibre architecture with
clearly abnormal nerve outgrowth and synapse for-
mation. This indicates that SLC25A1 is required for
normal NMJ formation. Of note, an SLC25A1 knock-
down zebrafish model was previously generated to
show the influence of SLC25A1 on embryogenesis,
mitochondrial DNA and autophagy; but limited details
of the fish phenotype and NMJ development were pro-
vided [14]. In addition to the NMJ abnormalities, we
demonstrate further alteration in brain and heart mor-
phology and development in the more severely affected
zebrafish morphants, compatible with a more general
function of SLC25A1 in mitochondria.
The mutation identified in this study (p.R247Q)
has a less deleterious effect when compared to other
SLC25A1 mutations described to date [17, 18]. This is
supported by the observed preserved protein expres-
sion in patient’s skin fibroblast with moderately
reduced carrier function and the low score from in
silico prediction.
In spite of a relevant difference between the scores of
R247 and other previously reported mutated residues
like G130 [17], the activity of the yeast orthologous
protein harboring either of the two pathogenic muta-
tions at equivalent positions is only 15% different,
i.e. 40% and 25%, respectively (Table 2 and Fig. 3).
Such observation may be the consequence of two
possible factors. First, the yeast model system may
not exactly reproduce the real activity of the human
mutated proteins. Although this cannot be excluded, it
appears unlikely since the yeast ortholog closely mir-
rors SLC25A1 for both protein sequence and citrate
transport activity. Furthermore, as far as the clini-
cal phenotype is concerned, it is worth recalling that
the p.G130D mutation is heterozygous and the other
affected allele harbors the p.R282H mutation [17]
which completely abolishes transport activity (Fig. 4).
Second, the score is an evolutionary based value, which
relies on the strength of natural selection and depends
on the fitness of organisms, i.e. the likelihood of organ-
isms to survive and generate fertile progeny [37]. The
present patients reached the reproductive age and they
may be considered fertile even if the protein activity
of the p.R247Q mutant is partially reduced. For this
reason the score of p.R247Q is expected to be much
lower compared to any other examinedSLC25A1muta-
tion that is instead responsible for premature death in
neonatal age. At the same time, this might explain
why G130 and R282 [17] as well other previously
reported pathogenic mutations [18] have very close
scores.
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We speculate that this mild manifestation of dis-
ease may have facilitated the detection of an NMJ
defect in our patient, while it remains undetected in
patients with the more disabling, often fatal form of
the disease. Further studies are required to elucidate
why the NMJ seems to be particularly sensitive to mild
SLC25A1 dysfunction, while other organs such as the
brain remain largely asymptomatic. Interestingly, the
knockdown experiments in zebrafish show a similar
dependency of symptoms in relation to the knockdown:
less severely affected zebrafish morphants show motil-
ity defects and NMJ abnormalities, but more severely
affected morphants have additional defects of the brain
and heart compatible with a generalized mitochondrial
defect.
Mitochondria are ubiquitous organelles that inter-
vene in a multitude of cellular functions including
energy production, cellular metabolism, calcium
homeostasis and apoptosis [10, 11]. The exact role of
mitochondria in synapse development remains poorly
understood and is likely to be complex. How defects in
a ubiquitous mitochondrial citrate carrier can manifest
primarily as a NMJ defect remains to be determined.
It is also worth emphasizing that SLC25A1 is likely
to be a very rare cause of a pure CMS phenotype.
We have screened undiagnosed CMS patients from
our extended cohorts and did not detect additional
pathogenic SLC25A1 variants. Exome sequencing
results from more than six thousand random individu-
als (Exome Variant Server; http://evs.gs.washington.
edu/EVS/, accessed April 2014), revealed only 15
missense mutations in SLC25A1. Each mutation is
heterozygous and present in less than 0.1% of the
screened population. At least seven of these mutations
are predicted to severely impair the protein func-
tion according to our scoring system and represent
an existing source of pathogenic alleles circulating in
the human population. Therefore, while the presence
of homozygous mutations or compound heterozygous
mutations in SLC25A1 is a rare event, should a patient
show fatigable weakness, one may wish to test for
SLC25A1 mutations and consider screening for car-
diac and metabolic defects should this be proven to be
culprit.
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Supplementary Video. Video footage of 48hpf
zebrafish embryos following co-injection of
SLC25A1a (5 ng) and SLC25A1b (2.5 ng): Mildly
(Top Right), moderately (Bottom Left), and severely
(Bottom Right) affected embryos demonstrate a
reduced heart rate compared to that of the non-injected
Wild Type Golden control embryos (Top Left)”.
Supplementary Figure 1. RT-PCR analysis of
SLC25A1 orthologs at different stages of zebrafish
development. Both SLC25A1 genes on Chr.10
(SLC25A1a & SLC25A1b) are expressed from 0.5
hours post fertilisation (hpf) and maintained through-
out development into adulthood. SLC25A1 gene on
Chr.8 is not expressed during zebrafish development or
adulthood. EF1: elongation factor 1 alpha was used
as internal RT-PCR control for all time points to certify
cDNA synthesis quality.
Supplementary Figure 2. Structural comparative
model of human CIC and docking of citrate. The
3D comparative model of human CIC is reported in
white cartoon representation. The six transmembrane
helices are indicated by black labels (H1-H6). The
three short helices parallel to the membrane planes
are also labelled (h12, h34, and h56). The citrate lig-
and is shown in cyan licorice. The residues forming
the m-gate are reported in black mesh representation.
Panel (A): lateral view of the human citrate carrier. Pro-
lines (magenta beads) and glycines (yellow beads) of
the PG levels (or the corresponding residues) surround
the substrate binding area. The pathogenic mutations
R247Q (this work), G130D and R282H are reported
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in red surf representation and are indicated by black
labels. Panel (B): Bottom view of the 3D comparative
model of human CIC. The pathogenic mutation R247Q
is reported in magenta licorice representation. R247
and E270 are reported in yellow sticks representation.
Black dashed lines indicate ionic bonds (both shorter
than 2.5 A˚). The symmetrical interactions observed on
the first and on the second repeat (K174-E149 and Q52-
H78, shown in white sticks representation) are also
reported for comparative purposes. Red dashed lines
indicate putative (water mediated) H-bond interactions
(among 5.5 and 6.5 A˚).
Supplementary Figure 3. Exploded view of the salt
bridge between R247 and E270 (panel A) and of the
putative H-bond interactions between Q247 and E270
(panel B). Colours and graphical representations as in
Supplementary Figure 2.
Supplementary Figure 4. Mitochondrial staining
in fibroblast cells relative to control and patient
(panel A). Mitochondrial Staining with Mitotracker
Mitochondrion-selective Probes- Medium containing
Mitotracker Red CMXRos in a range of 10–500 nM
was added to cells grown on tissue culture chamber
slides and incubated at 37◦C for 30–45 min. After incu-
bation, the medium containing the Mitotracker dye
was replaced with fresh medium, and the stained cells
were observed by fluorescence microscopy. The same
cells were used to measure mitochondrial membrane
potential using the tetramethylrhodamine methyl ester
(TMRM) probe.  measured as relative fluorescence
units (RFU) is presented as mean ± SD of three exper-
iments (panel B).
Supplementary Figure 5. RT-PCR analysis of
SLC25A1a and SLC25A1b MO induced phenotypes
at different stages of zebrafish development. Both
SLC25A1a & SLC25A1b induce splicing of the asso-
ciated genes on Chr.10 at both 24hpf and 48hpf.
Supplementary Figure 6. Percentage of pheno-
types observed in zebrafish following injection of
SLC25A1a+b MO in the presence and absence of
anti-p53 MO compared to non-injected control and
control MO injected embryos. Non-injected control
embryos and those injected with a standard control
MO showed similar percentage of survival. Combined
SLC25A1 MO with and without the addition of anti-
p53 MO demonstrate reduced percentage of survival.
Co-injection with anti-p53 MO displays a reduced per-
centage of severe phenotypes observed.
Supplementary Figure 7. Morphology of 48hpf
SLC25A1 morphant embryos. Live embryos imaged
at 48hpf following co-injection of SLC25A1a (5 ng),
SLC25A1b (2.5 ng) and anti-p53 MO. Embryos were
injected with an anti-p53 MO, suppressing the non-
specific MO mediated apoptotic affects produced by
p53 activation. Injected embryos also demonstrated a
range of phenotypes from mildly to severely affected.
Embryos exhibit a developmental delay with curva-
ture and shortening of the tail and also oedema of the
hindbrain, heart, yolk sac and tail. Scale bars: 500m.
Supplementary Figure 8. Neuromuscular junctions
following injection with SLC25A1 MOs and anti-
p53 MO. Embryos injected with a standard control
MO showed no signs of neuronal abnormality and
were indistinguishable from non-injected wild type
embryos. WilSLC25A1 MO injected embryos (cen-
tre and right) were stained for postsynaptic AChR
(-bungarotoxin, red staining) and presynaptic nerve
endings (SV2 antibody, green staining). Combined
SLC25A1 MO (a 5 ng & b 2.5 ng) with the addition
of anti-p53 MO injected 48hpf embryos also exhibit
shortening and branching of motor axons. Scale bar:
50m.
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